We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Goodwin Biotech, Rafagen In Cell Line Pact
News

Goodwin Biotech, Rafagen In Cell Line Pact

Goodwin Biotech, Rafagen In Cell Line Pact
News

Goodwin Biotech, Rafagen In Cell Line Pact

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Goodwin Biotech, Rafagen In Cell Line Pact"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Goodwin Biotechnology, Inc. (GBI) and Rafagen, Inc. have entered a collaboration agreement for cell line engineering and biological contract manufacturing. Terms of the agreement were not disclosed.

"We seek to address unmet needs of patients with inherited and acquired diseases," said Sung Ho Hahm, Ph.D., co-founder, president and chief executive officer of Rafagen.

Hahm continued, "With Rafagen's proprietary technology platforms, the highest producing cell lines will be established at a fraction of the time currently required. This translates the promise of science into tangible therapies that restore health and save lives."

"By collaborating with Rafagen for cell line engineering, we at GBI can expand our capabilities as a biological contract manufacturing organization and offer one-stop shopping," noted SooYoung Lee, Ph.D., senior vice president at GBI.

Lee continued, "This enables our clients to overcome challenging projects by working from their cDNA to develop more robust and high productivity cell lines that will not only scale up with greater efficiency, but by identifying cell lines with the highest level of efficacy, the end product will hopefully optimize patient outcomes."
Advertisement